Patents Represented by Attorney, Agent or Law Firm Michael A. Sanzo
  • Patent number: 7195748
    Abstract: The invention relates to a process for the production of hydrogen peroxide by the anthraquinone process, comprising a hydrogenation stage, an oxidation stage and an extraction stage. According to the invention, catalytic hydrogenation of anthraquinone derivatives dissolved in a working solution is carried out in the presence of added molecular oxygen. Per mol hydrogen, 0.1 to 10 mmol oxygen is preferably introduced into the hydrogenation stage with the hydrogenating gas, in mixture with an inert gas and/or dissolved and/or dispersed in the working solution. This increases the residence time of the catalyst.
    Type: Grant
    Filed: March 4, 2003
    Date of Patent: March 27, 2007
    Assignee: Degussa AG
    Inventors: Bernd Jaeger, Thomas Haas, Jürgen Glenneberg, Jürgen Grunert
  • Patent number: 6821751
    Abstract: The present invention is directed to DNA elements that enhance cellular gene expression in response to anaerobic growth or the presence of certain inducing agents. The enhancer element may be incorporated into expression vectors and used to increase the production of recombinant proteins.
    Type: Grant
    Filed: January 10, 2002
    Date of Patent: November 23, 2004
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Mark Alan Goldberg, Michael Vasconcelles, Yide Jiang
  • Patent number: 6800749
    Abstract: The present invention is directed to a novel neurotensin-like receptor expressed in the central nervous system of humans. The invention encompasses the receptor protein as well as nucleic acids encoding the protein. In addition, the invention is directed to methods and compositions which utilize the receptor.
    Type: Grant
    Filed: July 1, 1999
    Date of Patent: October 5, 2004
    Assignee: AstraZeneca Canada Inc.
    Inventors: Sultan Ahmad, Jack Cao, Dajan O'Donnell, Philippe Walker
  • Patent number: 6784210
    Abstract: The present invention is directed to a procedure for making an enantiomerically enriched compound containing a hydronaphthalene ring structure. The process involves reacting oxabenzonorbornadienes with nucleophiles using rhodium as a catalyst and in the presence of a phosphine ligand. The compounds synthesized may be used in pharmaceutical preparations for the treatment of a variety of diseases and conditions.
    Type: Grant
    Filed: December 12, 2002
    Date of Patent: August 31, 2004
    Assignee: AstraZeneca AB
    Inventors: Keith Fagnou, Mark Lautens
  • Patent number: 6784181
    Abstract: The present invention is directed to a compound of general formula (I), wherein R1 is selected from phenyl, pyridinyl, thiophenyl, furanyl, imidazolyl; each phenyl ring and heteroaromatic ring optionally and independently being further substituted by 1, 2 or 3 substituents selected from straight and branched C1-C6 alkyl, NO2, CF3, C1-C6 alkoxy, chloro, fluoro, bromo, and iodo, as well as their pharmaceutically acceptable salts. The invention includes pharmaceutical compositions comprising these compounds and the use of the compounds in therapy, in particular in the management of pain.
    Type: Grant
    Filed: October 21, 2002
    Date of Patent: August 31, 2004
    Assignee: AstraZeneca AB
    Inventors: William Brown, Christopher Walpole, Niklas Plobeck
  • Patent number: 6777561
    Abstract: Compounds of general formula I are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.
    Type: Grant
    Filed: June 1, 2000
    Date of Patent: August 17, 2004
    Assignee: AstraZeneca Canada Inc.
    Inventors: Daniel Delorme, Vlad Gregor, Edward Roberts, Eric Sun
  • Patent number: 6774132
    Abstract: The present invention relates to certain spirooxindole derivatives and to pharmaceutically acceptable salts thereof, which exhibit good analgesic properties and are effective in the treatment of chronic pain. The derivatives have the structure of formula I: wherein: Ar is benzene or pyridine; X is NHCO—; —CONH—; or —NH—SO2—; Y is a single bond; and Z is —CH═CHCH2.
    Type: Grant
    Filed: October 27, 2000
    Date of Patent: August 10, 2004
    Assignee: AstraZeneca AB
    Inventors: Alf Claesson, Britt-Marie Swahn, Odd-Geir Berge
  • Patent number: 6756387
    Abstract: Compounds of general formula I R1 is selected from any one of phenyl, pyridinyl, thienyl, furanyl, imidazolyl, triazolyl and thiazolyl; where each R1 phenyl ring and R1 heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents selected from straight and branched C1-C6 alkyl, NO2, CF3, C1-C6 alkoxy, chloro, fluoro, bromo, and iodo. The substitutions on the phenyl ring and on the heteroaromatic ring may take place in any position on said ring systems; are disclosed and claimed in the present application, as well as salts and pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.
    Type: Grant
    Filed: January 16, 2003
    Date of Patent: June 29, 2004
    Assignee: AstraZeneca AB
    Inventors: William Brown, Christopher Walpole, Zhongyong Wei
  • Patent number: 6753335
    Abstract: Compounds of general formula I R1 is selected from any one of phenyl, pyridinyl, thienyl, furanyl, imidazolyl, and triazolyl; where each R1 phenyl ring and R1 heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents selected from straight and branched C1-C6 alkyl, NO2, CF3, C1-C6 alkoxy, chloro, fluoro, bromo, and iodo. The substitutions on the phenyl ring and on the heteroaromatic ring may take place in any position on said ring systems; are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts and pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.
    Type: Grant
    Filed: January 21, 2003
    Date of Patent: June 22, 2004
    Assignee: AstraZeneca AB
    Inventors: William Brown, Christopher Walpole, Zhongyong Wei
  • Patent number: 6722062
    Abstract: The present invention is directed to a method for purifying polysaccharides capable of inducing the production of high titers of opsonic antibodies that kill strains of enterococcal bacteria. In addition, the invention is directed to the antigens produced by this purification method and to vaccines which utilize such antigens.
    Type: Grant
    Filed: March 11, 2002
    Date of Patent: April 20, 2004
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Gerald B. Pier, Johannes Huebner, Ying Wang, Lawrence Madoff
  • Patent number: 6710025
    Abstract: The present invention is directed to therapeutic methods that are based upon an ability to modulate cellular contraction. This is accomplished by administering agents that either inhibit or induce the activity of alpha-smooth muscle actin.
    Type: Grant
    Filed: May 23, 2000
    Date of Patent: March 23, 2004
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Myron Spector
  • Patent number: 6710179
    Abstract: Compounds of general formula (I) wherein m is 0 or 1, and n is 1 or 2; are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.
    Type: Grant
    Filed: April 15, 2002
    Date of Patent: March 23, 2004
    Assignee: AstraZeneca Canada Inc.
    Inventors: Benjamin Pelcman, Edward Roberts
  • Patent number: 6709651
    Abstract: The present invention is directed to methods of treating a wide variety of diseases, disorders and conditions characterized by excessive activity of substance P. The treatment involves administering peptidases that recognize and selectively cleave polypeptides at Xaa-Pro sequences.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: March 23, 2004
    Assignee: B.M.R.A. Corporation B.V.
    Inventors: Eric Grouzmann, Jean-Silvain Lacroix, Michel Monod
  • Patent number: 6703483
    Abstract: Compounds of the formula I are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, particular in the management of pain, and more particularly in the management of pain during labor.
    Type: Grant
    Filed: June 9, 2000
    Date of Patent: March 9, 2004
    Assignee: Cornell Research Foundation, Inc.
    Inventor: Peter Schiller
  • Patent number: 6696287
    Abstract: The present invention is directed to an apparatus that can be used for co-culturing bacteria and eukaryotic cells. The apparatus allows the bacteria to be grown under steady state conditions and then perfused over the eukaryotic cells. The invention also includes a variety of methods for studying the attachment and invasion of host eukaryotic cells by bacteria.
    Type: Grant
    Filed: March 19, 2002
    Date of Patent: February 24, 2004
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Lawrence C. Paoletti, Gennady Malin
  • Patent number: 6696447
    Abstract: The present application describes compounds of general formula I where R1 is selected from any one of pyridinyl, thienyl, furanyl, imidazolyl, and triazolyl; and where each R1 heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents selected from straight and branched C1-C6 alkyl, NO2, CF3, C1-C6 alkoxy, chloro, fluoro, bromo, and iodo. The substitutions on the heteroaromatic ring may take place in any position on the ring system. The invention also includes enantiomers, salts and pharmaceutical compositions containing the compounds. The compounds may be used in treating patients for pain.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: February 24, 2004
    Assignee: AstraZeneca AB
    Inventors: William Brown, Niklas Plobeck, Christopher Walpole
  • Patent number: 6696257
    Abstract: The present invention is directed to novel G protein-coupled receptors that are found predominantly in the dorsal root ganglia. The invention encompasses both the receptor proteins as well as nucleic acids encoding the proteins. In addition, the present invention is directed to methods and compositions which utilize the receptors.
    Type: Grant
    Filed: March 3, 1999
    Date of Patent: February 24, 2004
    Assignee: National Research Council of Canada
    Inventors: Sultan Ahmad, Denis Banville, Yves Fortin, Paola Lembo, Dajan O'Donnell, Shi-Hsiang Shen
  • Patent number: 6693117
    Abstract: Compounds of general formula (I) are disclosed and claimed in the present application, as well as their pharmaceutically acceptable salts, pharmaceutical compositions comprising the novel compounds and their use in therapy, in particular in the management of pain.
    Type: Grant
    Filed: August 19, 2002
    Date of Patent: February 17, 2004
    Assignee: AstraZeneca Canada Inc.
    Inventors: Daniel Delorme, Edward Roberts, Zhongyong Wei
  • Patent number: 6680318
    Abstract: The present application is directed to compounds having the general formula: and to the use of these compounds in therapeutic methods.
    Type: Grant
    Filed: October 21, 2002
    Date of Patent: January 20, 2004
    Assignee: AstraZeneca AB
    Inventors: William Brown, Christopher Walpole, Niklas Plobeck
  • Patent number: 6680321
    Abstract: Compounds of the formula (I) as well as their pharmaceutically acceptable salts, and pharmaceutical compositions comprising the novel compounds. The novel compounds of the formula (I) are useful in the management of pain.
    Type: Grant
    Filed: August 2, 2000
    Date of Patent: January 20, 2004
    Assignee: AstraZeneca Canada, Inc.
    Inventors: Edward Roberts, Niklas Plobeck, Claes Wahlestedt